Clinical parameters, BM plasma cell infiltration, and fluorescence in situ hybridization
DISEASE, T(14;16)(Q32;Q23), T(4;14)(P16;Q32), DEL(17)(P13), CHROMOSOMAL ABNORMALITIES, CREST
Thirty-four patients received BM biopsies from the iliac crest performed within 4 weeks of the [Cytogenetic analyses were performed on CD138-purified BM plasma cells. High-risk cytogenetics was defined as the presence of at least one of the following aberrations (cutoff, ≥ 10% of cells): del(17)(p13), t(4;14)(p16;q32), or t(14;16)(q32;q23) (21). For the definition of high-risk disease, the Revised International Staging System (R-ISS) score was defined. Based on this prognostic system, stage R-ISS I included patients of ISS stage I (serum β2-microglobulin level < 3.5 mg/L and serum albumin level ≥ 3.5 g/dL), no high-risk chromosomal abnormalities, and a normal lactate dehydrogenase (LDH) level; stage R-ISS III included ISS stage III (serum β2-microglobulin level > 5.5 mg/L) and high-risk chromosomal abnormalities or a high LDH level; stage R-ISS II included all the other possible combinations [